# Bosutinib In Subjects With Renal Impairment

> **NCT01233882** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 34 (actual)

## Conditions studied

- Renal Disease, End-Stage
- Renal Insufficiency, Chronic
- Renal Insufficiency, Acute

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Bosutinib
- **DRUG:** Bosutinib
- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT01233882
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233882, "Bosutinib In Subjects With Renal Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01233882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*